3rd Annual Ligase Targeting Drug Development Summit

Kongressthemen
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.

Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.

https://go.evvnt.com/1450513-2?pid=4832

Herr Alex Domingo